Lipocine (NASDAQ:LPCN) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.58 and traded as low as $2.01. Lipocine shares last traded at $2.05, with a volume of 95,897 shares changing hands.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LPCN. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research note on Friday, March 27th. Wall Street Zen downgraded Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, HC Wainwright reissued a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $15.00.

Lipocine Stock Up 0.5%

The firm has a fifty day moving average price of $2.63 and a 200-day moving average price of $5.58. The firm has a market cap of $16.89 million, a price-to-earnings ratio of -1.09 and a beta of 0.48.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.16 million. Equities research analysts anticipate that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Lipocine

In other news, Director John W. Higuchi bought 123,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The shares were acquired at an average cost of $2.05 per share, with a total value of $252,150.00. Following the transaction, the director owned 163,797 shares of the company’s stock, valued at $335,783.85. This represents a 301.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Mahesh V. Patel bought 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the transaction, the chief executive officer directly owned 160,679 shares in the company, valued at approximately $326,178.37. This trade represents a 18.43% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 213,000 shares of company stock worth $434,600 over the last ninety days. Corporate insiders own 6.35% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in shares of Lipocine by 3.6% in the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares during the period. Geode Capital Management LLC raised its position in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after buying an additional 1,374 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after buying an additional 6,982 shares during the period. Jane Street Group LLC purchased a new position in shares of Lipocine in the 4th quarter worth $85,000. Finally, Citadel Advisors LLC purchased a new position in shares of Lipocine in the 3rd quarter worth $41,000. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.